In one large, multi-year study, patients with diabetes who were treated with the popular oral medication metformin face a lower risk of heart attack, stroke or death than those taking sulfonylureas, another common option. The findings are published in the Nov. 6 issue of the journal Annals of Internal Medicine.
|The blooming French lilac is rich |
in guanidine. The plant's hypoglycemic
properties led to the synthesis of the
biguanide compound metformin.
Researchers who tracked hundreds of thousands of veterans with type 2 diabetes found that users of metformin (brand names include Glucophage and Fortamet) faced a "modest but clinically important" 21 percent lower risk of hospitalization because of cardiovascular complications than users of sulfonylureas (glyburide and glipizide).
The researchers cautioned, however, that they couldn't pinpoint whether metformin protects against heart issues or whether, by contrast, sufonylureas pose a specific threat to heart health. It's possible that both are true.
Although the researchers said the findings suggest metformin should be the preferred oral treatment for diabetes, they also stressed that it's not yet clear whether their findings would apply to women or other racial and ethnic groups, given that 97 percent of their study participants were men and 75 percent were white.
"Metformin and sulfonylureas are the two most commonly prescribed medications for type 2 diabetes treatment," said study lead author Dr. Christianne Roumie, of the Geriatric Research Education Clinical Center at the Nashville Veterans Affairs Medical Center in Tennessee. "Both do a very good job of controlling a patient's blood sugar level."
However, "metformin may do a better job at preventing hospitalization for heart attacks and strokes or death," she added. "Because of this it should be preferred as the starting medication for patients with diabetes."
About 8 percent of people in the United States have diabetes. Most have type 2 diabetes, which means they don't metabolize blood sugar (glucose) properly.
According to the American Diabetes Association, sulfonylurea drugs are insulin-production stimulants while Metformin, which has been around since the 1950s, works by lowering blood glucose levels.
To compare the impact of the two drugs on cardiovascular results, the authors focused on a pool of more than 250,000 veterans over age 18 who started treatment with one of the two medications between 2001 and 2008.
Nearly 100,000 were placed on a standard regimen of sulfonylurea therapy, while roughly 155,000 took metformin. None had any serious medical complications other than diabetes at the start of the study.
A statistical analysis revealed that for every 1,000 patients who took metformin for one year there were two fewer heart attacks, strokes or deaths relative to those taking sulfonylureas, Roumie said.
The authors noted that their current observations were consistent with prior indications that metformin is associated with fewer serious heart issues than sulfonylurea.
In an editorial in the same journal, Dr. Steven Nissen, chairman of the department of cardiovascular medicine at the Cleveland Clinic in Ohio, agreed that the study's findings do point to metformin as a better choice for diabetes treatment, while calling for more research.
"While the signals pointing to this situation have probably been there for several decades the [U.S. Food and Drug Administration] did not require testing for cardiovascular outcomes when looking at diabetes drugs until very recently," Nissen said. "Which means the industry has developed drugs solely based on their ability to lower blood sugar."
At least two-thirds of people with diabetes will die of heart disease, Nissen added.
"The kind of information provided by a study like this on a diabetes drug's impact on heart disease is pretty important to have, when you think of it in that context," he said.
Metformin & Cancer Studies
A large case-control study conducted at M.D. Anderson Cancer Center has suggested metformin may protect against pancreatic cancer. The risk of pancreatic cancer in study participants having taken metformin was found to be 62% lower than in participants never having taken it, whereas participants who had used insulin or secretagogues (such as the sulfonylureas) were found to have a 5-fold and 2.5-fold higher risk of pancreatic cancer, respectively, compared to participants that had been treated with neither.
Observational studies conducted by the University of Dundee have shown a decrease of 25–37% in cancer cases in diabetics taking metformin. Several epidemiological and case-controlled studies found diabetics using metformin may have lower cancer risk in comparison to those using other antidiabetic medications. The causes of this phenomenon are unclear, and the results require confirmation in controlled studies but a direct action of metformin on cancer cells is suspected. Indeed, metformin exhibits a strong and consistent antiproliferative action on several cancer cell lines, including breast, colon, ovarian, pancreatic, lung and prostate cancer cells. These cellular studies were generally completed by preclinical studies showing a reliable antitumoral effect in various mouse models. In addition, the first clinical trials demonstrated a beneficial effect in breast and colon cancer.
Based on this new research, it looks like a good idea to talk to your doctor about switching to metformin